VenomAid Diagnostics ApS: Financial statements 2020
CVR: 39981165
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
VenomAid Diagnostics ApS (CVR 39981165) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 55,000 and a net result of DKK 19,520. The profit margin was 35.5%. Equity in the 2020 report amounted to DKK 118,424. The solvency ratio was 87.5%.
- Revenue
- DKK 55,000
- Gross Profit
- DKK 25,026
- Profit/Loss
- DKK 19,520
- Equity
- DKK 118,424
- Total Assets
- DKK 135,332
Official annual report
How creditworthy is VenomAid Diagnostics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of November 15, 2020, Jonas Arnold Jürgensen-Breum is registered as director of VenomAid Diagnostics ApS.
As of November 15, 2020, Rasmus Aasbjerg Friis has stepped down as director of VenomAid Diagnostics ApS.
VenomAid Diagnostics ApS has published its interim report for the period October 29, 2018 – December 31, 2019.
About VenomAid Diagnostics ApS
VenomAid Diagnostics ApS is a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Jonas Arnold Jürgensen-Breum. The board consists of Gert Fisker Tomczyk (chair), Andreas Hougaard Laustsen-Kiel, Mads Aage Laustsen and Morten Boje Munk. The company's owners include LAUSTSEN VENTURES ApS, Moleculo Holdings ApS and Ubia Holdings ApS. According to the 2025 annual report, the company had an average of 5 employees. In 2025, the company reported a gross profit of DKK -867,480 and a net result of DKK -3,853,829 compared with DKK -3,694,270 the year before. Equity in the 2025 report amounted to DKK -11,289,971.